Cargando…

Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection

Growth and differentiation factor 15 (GDF‐15), also known as macrophage inhibitory cytokine 1 (MIC‐1), may act as both a tumor suppressor and promotor and, by regulating NF‐κB and macrophage signaling, promote early prostate carcinogenesis. To determine whether expression of these two inflammation‐r...

Descripción completa

Detalles Bibliográficos
Autores principales: Rybicki, Benjamin A., Sadasivan, Sudha M., Chen, Yalei, Kravtsov, Oleksandr, Palangmonthip, Watchareepohn, Arora, Kanika, Gupta, Nilesh S., Williamson, Sean, Bobbitt, Kevin, Chitale, Dhananjay A., Tang, Deliang, Rundle, Andrew G., Iczkowski, Kenneth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085972/
https://www.ncbi.nlm.nih.gov/pubmed/33784024
http://dx.doi.org/10.1002/cam4.3850
_version_ 1783686437113167872
author Rybicki, Benjamin A.
Sadasivan, Sudha M.
Chen, Yalei
Kravtsov, Oleksandr
Palangmonthip, Watchareepohn
Arora, Kanika
Gupta, Nilesh S.
Williamson, Sean
Bobbitt, Kevin
Chitale, Dhananjay A.
Tang, Deliang
Rundle, Andrew G.
Iczkowski, Kenneth A.
author_facet Rybicki, Benjamin A.
Sadasivan, Sudha M.
Chen, Yalei
Kravtsov, Oleksandr
Palangmonthip, Watchareepohn
Arora, Kanika
Gupta, Nilesh S.
Williamson, Sean
Bobbitt, Kevin
Chitale, Dhananjay A.
Tang, Deliang
Rundle, Andrew G.
Iczkowski, Kenneth A.
author_sort Rybicki, Benjamin A.
collection PubMed
description Growth and differentiation factor 15 (GDF‐15), also known as macrophage inhibitory cytokine 1 (MIC‐1), may act as both a tumor suppressor and promotor and, by regulating NF‐κB and macrophage signaling, promote early prostate carcinogenesis. To determine whether expression of these two inflammation‐related proteins affect prostate cancer susceptibility, dual immunostaining of benign prostate biopsies for GDF‐15 and NF‐κB was done in a study of 503 case‐control pairs matched on date, age, and race, nested within a historical cohort of 10,478 men. GDF‐15 and NF‐κB expression levels were positively correlated (r = 0.39; p < 0.0001), and both were significantly lower in African American (AA) compared with White men. In adjusted models that included both markers, the odds ratio (OR) for NF‐κB expression was statistically significant, OR =0.87; p = 0.03; 95% confidence interval (CI) =0.77–0.99, while GDF‐15 expression was associated with a nominally increased risk, OR =1.06; p = 0.27; 95% CI =0.96–1.17. When modeling expression levels by quartiles, the highest quartile of NF‐κB expression was associated with almost a fifty percent reduction in prostate cancer risk (OR =0.51; p = 0.03; 95% CI =0.29–0.92). In stratified models, NF‐κB had the strongest negative association with prostate cancer in non‐aggressive cases (p = 0.03), older men (p = 0.03), and in case‐control pairs with longer follow‐up (p = 0.02). Risk associated with GDF‐15 expression was best fit using nonlinear regression modeling where both first (p = 0.02) and second (p = 0.03) order GDF‐15 risk terms were associated with significantly increased risk. This modeling approach also revealed significantly increased risk associated with GDF‐15 expression for subsamples defined by AA race, aggressive disease, younger age, and in case‐control pairs with longer follow‐up. Therefore, although positively correlated in benign prostatic biopsies, NF‐κB and GDF‐15 expression appear to exert opposite effects on risk of prostate tumor development.
format Online
Article
Text
id pubmed-8085972
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80859722021-05-07 Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection Rybicki, Benjamin A. Sadasivan, Sudha M. Chen, Yalei Kravtsov, Oleksandr Palangmonthip, Watchareepohn Arora, Kanika Gupta, Nilesh S. Williamson, Sean Bobbitt, Kevin Chitale, Dhananjay A. Tang, Deliang Rundle, Andrew G. Iczkowski, Kenneth A. Cancer Med Clinical Cancer Research Growth and differentiation factor 15 (GDF‐15), also known as macrophage inhibitory cytokine 1 (MIC‐1), may act as both a tumor suppressor and promotor and, by regulating NF‐κB and macrophage signaling, promote early prostate carcinogenesis. To determine whether expression of these two inflammation‐related proteins affect prostate cancer susceptibility, dual immunostaining of benign prostate biopsies for GDF‐15 and NF‐κB was done in a study of 503 case‐control pairs matched on date, age, and race, nested within a historical cohort of 10,478 men. GDF‐15 and NF‐κB expression levels were positively correlated (r = 0.39; p < 0.0001), and both were significantly lower in African American (AA) compared with White men. In adjusted models that included both markers, the odds ratio (OR) for NF‐κB expression was statistically significant, OR =0.87; p = 0.03; 95% confidence interval (CI) =0.77–0.99, while GDF‐15 expression was associated with a nominally increased risk, OR =1.06; p = 0.27; 95% CI =0.96–1.17. When modeling expression levels by quartiles, the highest quartile of NF‐κB expression was associated with almost a fifty percent reduction in prostate cancer risk (OR =0.51; p = 0.03; 95% CI =0.29–0.92). In stratified models, NF‐κB had the strongest negative association with prostate cancer in non‐aggressive cases (p = 0.03), older men (p = 0.03), and in case‐control pairs with longer follow‐up (p = 0.02). Risk associated with GDF‐15 expression was best fit using nonlinear regression modeling where both first (p = 0.02) and second (p = 0.03) order GDF‐15 risk terms were associated with significantly increased risk. This modeling approach also revealed significantly increased risk associated with GDF‐15 expression for subsamples defined by AA race, aggressive disease, younger age, and in case‐control pairs with longer follow‐up. Therefore, although positively correlated in benign prostatic biopsies, NF‐κB and GDF‐15 expression appear to exert opposite effects on risk of prostate tumor development. John Wiley and Sons Inc. 2021-03-30 /pmc/articles/PMC8085972/ /pubmed/33784024 http://dx.doi.org/10.1002/cam4.3850 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Rybicki, Benjamin A.
Sadasivan, Sudha M.
Chen, Yalei
Kravtsov, Oleksandr
Palangmonthip, Watchareepohn
Arora, Kanika
Gupta, Nilesh S.
Williamson, Sean
Bobbitt, Kevin
Chitale, Dhananjay A.
Tang, Deliang
Rundle, Andrew G.
Iczkowski, Kenneth A.
Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
title Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
title_full Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
title_fullStr Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
title_full_unstemmed Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
title_short Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
title_sort growth and differentiation factor 15 and nf‐κb expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085972/
https://www.ncbi.nlm.nih.gov/pubmed/33784024
http://dx.doi.org/10.1002/cam4.3850
work_keys_str_mv AT rybickibenjamina growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection
AT sadasivansudham growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection
AT chenyalei growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection
AT kravtsovoleksandr growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection
AT palangmonthipwatchareepohn growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection
AT arorakanika growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection
AT guptanileshs growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection
AT williamsonsean growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection
AT bobbittkevin growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection
AT chitaledhananjaya growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection
AT tangdeliang growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection
AT rundleandrewg growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection
AT iczkowskikennetha growthanddifferentiationfactor15andnfkbexpressioninbenignprostaticbiopsiesandriskofsubsequentprostatecancerdetection